Back to Stocks

QURE

uniQure N.V.
6 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

uniQure is demonstrating a disciplined transition toward a leaner, more focused operational model. By strategically reducing R&D overhead and discontinuing the AMT-162 program, management has optimized its burn rate while maintaining a robust cash position of $586.6 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite a seemingly large cash balance, uniQure's financial health is compromised by a complex web of debt and liabilities. The company carries $482 million in royalty-financing debt with high effective interest rates, alongside a $50 million senior loan.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every QURE filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical juncture, balancing a strong current liquidity position against mounting debt and rigorous regulatory demands. The shift toward a leaner R&D structure and the termination of complex manufacturing agreements with Genezen and CSL Behring indicate a strategic effort to simplify operations. However, the widening net loss to $53.5 million highlights the persistent cost of maintaining a clinical-stage biotech operation. Investors must weigh the positive momentum of the HEMGENIX royalties and the UK MHRA filing against the FDA's demand for a full Phase III trial for AMT-130. The ultimate trajectory of the stock will likely depend on whether the company can successfully initiate and fund these pivotal trials without significant further dilution, all while managing the interest burden of its royalty financing agreement.

Selected Quarter

Core Takeaway

The company is trading short-term operational losses for a long-term strategic runway, but the FDA's requirement for a randomized Phase III trial for AMT-130 significantly increases the cost and time to market.

Investor Lens

The trade-off is between the company's current liquidity and the increased capital intensity of the newly mandated regulatory path.

Watch Next

The initiation of the randomized Phase III trial for AMT-130 and the Q3 2026 UK MHRA application submission.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.25Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 5

Net loss widened to $53.5 million from $43.6 million YoY due to rising SG&A and interest expenses.

margin compression
60%
bearishMay 5

FDA rejected accelerated BLA pathway for AMT-130, requiring a full randomized Phase III trial.

regulatory action
80%
bullishMay 5

License revenues increased to $3.6 million from $1.6 million YoY.

earnings beat
40%
neutralMay 5

Amended venture debt facility with Hercules Capital to improve terms.

debt restructure
30%
bearishMay 5

Net loss widened to $53.5 million from $43.6 million YoY due to rising SG&A and interest expenses.

margin compression
60%
bearishMay 5

FDA rejected accelerated BLA pathway for AMT-130, requiring a full randomized Phase III trial.

regulatory action
80%
bullishMay 5

License revenues increased to $3.6 million from $1.6 million YoY.

earnings beat
40%
neutralMay 5

Amended venture debt facility with Hercules Capital to improve terms.

debt restructure
30%
bearishMay 5

Net loss widened to $53.5 million from $43.6 million YoY due to rising SG&A and interest expenses.

margin compression
60%
bearishMay 5

FDA rejected accelerated BLA pathway for AMT-130, requiring a full randomized Phase III trial.

regulatory action
80%
bullishMay 5

License revenues increased to $3.6 million from $1.6 million YoY.

earnings beat
40%
neutralMay 5

Amended venture debt facility with Hercules Capital to improve terms.

debt restructure
30%
bearishMay 5

Net loss widened to $53.5 million from $43.6 million YoY due to rising SG&A and interest expenses.

margin compression
60%
bearishMay 5

FDA rejected accelerated BLA pathway for AMT-130, requiring a full randomized Phase III trial.

regulatory action
80%
bullishMay 5

License revenues increased to $3.6 million from $1.6 million YoY.

earnings beat
40%
neutralMay 5

Amended venture debt facility with Hercules Capital to improve terms.

debt restructure
30%
bearishMay 5

Net loss widened to $53.5 million from $43.6 million YoY due to rising SG&A and interest expenses.

margin compression
60%
bearishMay 5

FDA rejected accelerated BLA pathway for AMT-130, requiring a full randomized Phase III trial.

regulatory action
80%
bullishMay 5

License revenues increased to $3.6 million from $1.6 million YoY.

earnings beat
40%
neutralMay 5

Amended venture debt facility with Hercules Capital to improve terms.

debt restructure
30%
bearishMay 5

Net loss widened to $53.5 million from $43.6 million YoY due to rising SG&A and interest expenses.

margin compression
60%
bearishMay 5

FDA rejected accelerated BLA pathway for AMT-130, requiring a full randomized Phase III trial.

regulatory action
80%
bullishMay 5

License revenues increased to $3.6 million from $1.6 million YoY.

earnings beat
40%
neutralMay 5

Amended venture debt facility with Hercules Capital to improve terms.

debt restructure
30%

Filing History

10-QMay 5, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical juncture, balancing a strong current liquidity position against mounting debt and rigorous regulatory demands. The shift toward a leaner R&D structure and the termination of complex manufacturing agreements with Genezen and CSL Behring indicate a strategic effort to simplify operations. However, the widening net loss to $53.5 million highlights the persistent cost of maintaining a clinical-stage biotech operation. Investors must weigh the positive momentum of the HEMGENIX royalties and the UK MHRA filing against the FDA's demand for a full Phase III trial for AMT-130. The ultimate trajectory of the stock will likely depend on whether the company can successfully initiate and fund these pivotal trials without significant further dilution, all while managing the interest burden of its royalty financing agreement.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.